syn-004
Small moleculeexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2015 (NCT02391727)
Timeline
Indications
Mechanism of action
- ADC-11INHIBITOR
ampC inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- syn004
- syn-004
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04363242 | Phase 1 | Apr 9, 2020 | Henry Ford Health System, Synermore Biologics Co., Ltd. |
| NCT02563106 | Phase 2 | Oct 1, 2015 | Synthetic Biologics |
| NCT02473640 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2015 | Synthetic Biologics |
| NCT02391727 | Phase 1 | Mar 1, 2015 | Synermore Biologics Co., Ltd. |
| NCT02419001 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2015 | Synthetic Biologics |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Synthetic Biologics | For profit | 3 | 3 | 1 | 2015 |
| Synermore Biologics Co., Ltd. | For profit | 2 | 2 | 1 | 2015 |
| Henry Ford Health System | Academic/Hospital | 1 | 0 | 1 | 2020 |
3 organizations
Page 1 / 1